Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yesmin Fadul Paulino

General Practice Bayamon, PR Medical Doctor

NPI 1104810373 CMS profile 964218

73 Calle Santa Cruz, Santa Cruz Medical Bldg Ste 409, Bayamon, PR 00961

Open in the dashboard

General payments

$3,725

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yesmin Fadul Paulino of Bayamon, PR is reported in the CMS Open Payments database as having received $3,725 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $242 10
2024 General $296 13
2023 General $615 23
2022 General $722 35
2021 General $758 38
2020 General $278 14
2019 General $814 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yesmin Fadul Paulino
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Yesmin Fadul Paulino were reported at $242. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Yesmin Fadul Paulino General Practice median Middle half National median
2019 $814 $107 $37–$285 $163
2020 $278 $75 $25–$213 $114
2021 $758 $93 $30–$272 $132
2022 $722 $103 $36–$279 $149
2023 $615 $106 $34–$276 $160
2024 $296 $114 $39–$290 $164
2025 $242 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $929 38 payments
  2. AstraZeneca Pharmaceuticals LP $783 40 payments
  3. Eli Lilly Export S.A. Puerto Rico Branch $363 18 payments
  4. Janssen Pharmaceuticals, Inc $259 12 payments
  5. Merck Sharp & Dohme Corporation $257 13 payments
  6. Sanofi-Aventis U.S. LLC $216 10 payments
  7. Novo Nordisk Inc $194 10 payments
  8. E.R. Squibb & Sons, L.L.C. $184 9 payments
  9. Lilly USA, LLC $169 3 payments
  10. PBG Puerto Rico LLC $116 5 payments
  11. Other $254 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,725 169 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $595 30 payments
  2. JARDIANCE Diabetes $494 20 payments
  3. JARDIANCE Diabetes $270 11 payments
  4. XARELTO $259 12 payments
  5. JANUVIA $217 11 payments
  6. ELIQUIS $184 9 payments
  7. MOUNJARO $184 4 payments
  8. Ozempic $174 9 payments
  9. RYBELSUS $174 9 payments
  10. SPIRIVA RESPIMAT $165 7 payments
  11. Other $2,455 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record